Innate Pharma (IPHA) Net Income towards Common Stockholders (2018 - 2026)
Innate Pharma (IPHA) recorded Net Income towards Common Stockholders of -$22.81 million in the quarter ended Jun 30, 2026, compared with -$24.16 million a year earlier.
Powered by 
Analysis
Innate Pharma (IPHA) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
On a TTM basis, Innate Pharma's Net Income towards Common Stockholders came in at -$157.08 million as of Jun 30, 2026; for the year ended Dec 31, 2025, it was -$55.56 million.
- Across earlier years, Net Income towards Common Stockholders came in at -$53.54 million in the year ended Dec 31, 2024, -$8.19 million in the year ended Dec 31, 2023, -$61.24 million in the year ended Dec 31, 2022 and -$60.41 million in the year ended Dec 31, 2021.
- The figure for the quarter ended Jun 30, 2026 is the highest quarterly Net Income towards Common Stockholders since the quarter ended Dec 31, 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Innate Pharma | 146.20 Mn | 146.20 Mn | - | -22.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.81 Mn |
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -59.28 Mn |
| Jun 30, 2022 | -77,895.14 |
| Dec 31, 2021 | -60.41 Mn |
| Jun 30, 2021 | -28.56 Mn |
| Dec 31, 2020 | -76.29 Mn |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |
| Dec 31, 2018 | 3.48 Mn |
API Access
Innate Pharma Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IPHA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "IPHA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IPHA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();